Dataset Information
Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia.
Ontology highlight
ABSTRACT:
SUBMITTER: Calvopina K
PROVIDER: S-EPMC6985731 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
Publications
Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia.
Antimicrobial agents and chemotherapy 20200127 2
Aminoglycoside resistance in <i>Stenotrophomonas maltophilia</i> is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory-selected mutants and clinical isolates, we show here that damage to the 50S ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of <i>smeYZ</i> These findings explain the role of SmeYZ in both intrinsic and mutational ...[more]